Also listed under Urinary Bladder Diseases
ClinicalTrials.gov term: Urinary Bladder Neoplasms
Bladder Cancer clinical trials
Data updated daily from ClinicalTrials.gov, last refresh 2026-11-08
What changed in the last 30 days
96 trials changed in the last 30 days: 1 stopped, 38 with notable changes, 57 with minor changes only.
-
Minor: 7 trials marked Unknown by the registry's verification sweep Changed
- Minor: JK08 · Unresectable Locally Advanced or Metastatic Cancer Changed Registry marked status Unknown (sponsor has not verified the record since Oct 2024); last known: Active, Not Recruiting
- Minor: NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors Changed Registry marked status Unknown (sponsor has not verified the record since Oct 2024); last known: Active, Not Recruiting
- Minor: GENSA · Immediate Postoperative Intravesical Instillation With Either Gemcitabine or Epirubicin · Urinary Bladder Cancer (Gemcitabine Epirubicin Normal SAline) Changed Registry marked status Unknown (sponsor has not verified the record since Jan 2022); last known: Recruiting
- Minor: Can Second Resection for pT1 Bladder Cancer be Avoided After Initial En-Bloc Resection With Negative Safety Margins Changed Registry marked status Unknown (sponsor has not verified the record since Oct 2024); last known: Recruiting
- Minor: LaserEn · SOLTIVE™ Thulium Laser Fiber En Bloc Resection of Bladder Tumors Changed Registry marked status Unknown (sponsor has not verified the record since Oct 2024); last known: Recruiting
- Minor: Can VI-RADS/ADC Accurately Stage Bladder Cancer?? Changed Registry marked status Unknown (sponsor has not verified the record since Oct 2024); last known: Active, Not Recruiting
- Minor: IMOPU · Urothelium Tissue Engineering Using Biopsies From Transurethral Resection of Prostate Changed Registry marked status Unknown (sponsor has not verified the record since Sep 2018); last known: Not Yet Recruiting
- Notable: At-Home Cancer Directed Therapy Versus in Clinic · Advanced Cancer Primary completion pushed from Jan 1, 2027 to Dec 1, 2027
- Notable: TroFuse-055 · Sacituzumab Tirumotecan (Sac-TMT, MK-2870) and Pembrolizumab (MK-3475A) · Bladder Cancer (MK-2870-055) Recruitment opened
- Minor: IMvigor011 · Atezolizumab Versus Placebo as Adjuvant Therapy · High-risk Muscle-invasive Bladder Cancer (MIBC) Who Are ctDNA Positive Following Cystectomy Trial completed
- Minor: Prophylactic Antibiotics in Cystectomy With Diversion Trial completed
- Minor: INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) · Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist) Trial sites expanded: 42 → 60 locations
- Notable: Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab · Advanced or Metastatic Malignancy or Other Benign Disease Results posted: Nov 5, 2026
- Minor: TroFuse-027 · Sacituzumab Tirumotecan (MK-2870) · Bladder Cancer (MK-2870-027) Trial completed
- Minor: Association of POCD With Circulating Biomarkers in Patients Undergoing TUR of Bladder Tumor Enrollment closed, study ongoing
- Minor: Education and Navigation Support Tool to Improve Participation in Care Coordination · Locally Advanced, Metastatic and Unresectable Bladder Cancer and Their Caregivers Study completion pushed from Sep 30, 2026 to Sep 25, 2027
- Notable: CAMPERR · CfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease Primary completion pushed from Mar 2026 to Dec 31, 2026
- Minor: IMCODE004 · Autogene Cevumeran With Nivolumab Versus Nivolumab Alone · High-risk Muscle-invasive Urothelial Carcinoma (MIUC) Trial sites reduced: 43 → 38 locations
- Minor: Zanidatamab · HER2-expressing Tumors Trial sites expanded: 28 → 42 locations
- Minor: Collecting Blood Samples From · and Without Cancer to Evaluate Tests for Early Cancer Detection Trial sites expanded: 747 → 751 locations
- Minor: DEFEND · Distance-Based Exercise to Preserve Function and Prevent Disability Trial sites expanded: 23 → 30 locations
- Minor: Vanguard Study: Testing a New Way to Screen for Cancer Interventions modified
- Stopped: NeoSTOP-IT · Gemcitabine/Cisplatin Plus Cemiplimab With or Without Fianlimab in Localized Muscle-invasive Bladder Cancer Trial terminated
- Notable: Performance, Feasibility, and Safety Study for a Novel Endoluminal Robotic System for En-Bloc Resection of Bladder Tumours: First-In-Human Trial Primary completion pushed from Dec 31, 2027 to Dec 31, 2028
- Notable: Disitamab Vedotin Plus Intravesical Mitomycin C in HER2-Expressing Intermediate- to High-Risk Non-Muscle-Invasive Bladder Cancer Enrollment increased: 30 → 50 participants
- Notable: Guiding Value of Urinary Tumor DNA Testing in Repeat Transurethral Resection of Non-Muscle-Invasive Bladder Cancer Enrollment increased: 196 → 350 participants
- Stopped: terminated, suspended or withdrawn
- Notable: the plan changed
- Minor: routine updates
New sponsor entrants, last 90 days sponsors with their first trial in this area
| First posted | Trial | Sponsor | Phase |
|---|---|---|---|
| 2026-10-27 | NCT07898033 1 Year Recurrence After Modified en Bloc Resection (ERBT) vs Transurethral Resection… | dmitry enikeev new | Phase 3 |
| 2026-10-26 | NCT07893509 Outcomes for IR and High Risk (HR) Non-muscle Invasive Bladder Cancer (NMIBC) and… | Bladder Cancer Advocacy Network new | |
| 2026-10-19 | NCT07881666 Inactivated UPEC-FimON for Non Muscle Invasive Bladder Cancer After BCG or Intravesical… | Hopec Pharma new | Phase 1 |
| 2026-10-06 | NCT07860398 Feasibility of Automatic, Laser-based Distance Control in Persons With Superficial… | Optheras AS new | |
| 2026-10-02 | NCT07855926 Perioperative Systemic Therapies in Muscle-Invasive Bladder Cancer (GUARDIANS) | LMU Klinikum new | |
| 2026-09-11 | NCT07815665 A Study of Ivonescimab in Combination With Enfortumab Vedotin vs Pembrolizumab in… | Summit Therapeutics new | Phase 2/3 |
| 2026-09-08 | NCT07808216 Toripalimab Combined With Intravesical Gemcitabine as Adjuvant Therapy for High-Risk… | Tianjin First Central Hospital new | Phase 2 |
| 2026-08-28 | NCT07793318 TR115 in ARID1A-Mutated Advanced Solid Tumors | Tarapeutics Science Inc. new | Phase 2 |
| 2026-08-25 | NCT07784387 A Study to Characterize High-Risk Non-Muscle-Invasive Bladder Cancer Participants in… | Janssen-Cilag Farmaceutica Ltda. new | |
| 2026-08-24 | NCT07781852 Evaluation of the Distribution of 64Cu/68Ga Labeled CM500 in Healthy Volunteers and… | Lumina Pharmaceuticals Inc new | Early Phase 1 |
Active trials by phase
| Early Phase 1 | 14 | |
| Phase 1 | 111 | |
| Phase 1/2 | 85 | |
| Phase 2 | 216 | |
| Phase 2/3 | 15 | |
| Phase 3 | 86 | |
| Phase 4 | 11 |
Not charted: 350 active trials with no phase listed on ClinicalTrials.gov (typically behavioural, device, procedure and observational studies).
Top sponsors by active trials in this area
National Cancer Institute (NCI) (36) · Memorial Sloan Kettering Cancer Center (20) · Peking University First Hospital (18) · M.D. Anderson Cancer Center (17) · AstraZeneca (15) · Mayo Clinic (13) · Merck Sharp & Dohme LLC (13) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (12) · Janssen Research & Development, LLC (11) · Tianjin Medical University Second Hospital (11)
Get alerts when Bladder Cancer trials change
Status changes, date slips, and new sponsor entrants: detected daily, delivered to your inbox.